文献速递淋巴瘤

CAR-T细胞疗法在老年复发/难治性弥漫性大B细胞淋巴瘤患者中的真实世界经验

Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma.
PubMed 文献 · Blood · 2023-01-01

利用100% Medicare按服务收费理赔数据库,分析2018至2020年间接受CAR-T细胞疗法的551例≥65岁DLBCL老年患者。中位无事件生存期为7.2个月,≥75岁患者12个月无事件生存率显著低于65-69岁和70-74岁组(34% vs 43% vs 52%,P=.002)。中位总生存期为17.1个月,各年龄组无显著差异。

要点

  • ≥75岁患者12个月无事件生存率为34%,低于65-69岁的43%和70-74岁的52%(P=.002)。
  • 中位总生存期为17.1个月,各年龄组间无显著差异。
  • 83%患者在住院环境下接受CAR-T细胞疗法,平均住院天数为21天。

核心结论

  • CAR-T细胞疗法与较好的有效性相关,但老年患者使用率低,尤其≥75岁患者,且该年龄组无事件生存率更低,说明老年患者尤其≥75岁患者对更可及、有效且可耐受的治疗存在未满足需求。

研究设计与样本

  • 利用100% Medicare按服务收费理赔数据库,分析2018至2020年间接受CAR-T细胞疗法的551例≥65岁DLBCL老年患者。

主要发现

  • 65至69岁患者中19%在三线及以上接受CAR-T细胞疗法,70至74岁为22%,≥75岁为13%。
  • 大多数患者(83%)在住院环境下接受CAR-T细胞疗法,平均住院天数为21天。
  • CAR-T细胞疗法后中位无事件生存期为7.2个月。
  • ≥75岁患者无事件生存期显著短于65至69岁和70至74岁患者,12个月无事件生存率分别为34%、43%和52%(P=.002)。
  • 中位总生存期为17.1个月,各年龄组间无显著差异;90天随访期间中位总医疗费用为352572美元,各年龄组相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The emergence of chimeric antigen receptor (CAR) T-cell therapy has changed the treatment landscape for diffuse large B-cell lymphoma (DLBCL); however, real-world experience reporting outcomes among older patients treated with CAR T-cell therapy is limited. We leveraged the 100% Medicare fee-for-service claims database and analyzed outcomes and cost associated with CAR T-cell therapy in 551 older patients (aged ≥65 years) with DLBCL who received CAR T-cell therapy between 2018 and 2020. CAR T-cell therapy was used in third line and beyond in 19% of patients aged 65 to 69 years and 22% among those aged 70 to 74 years, compared with 13% of patients aged ≥75 years. Most patients received CAR T-cell therapy in an inpatient setting (83%), with an average length of stay of 21 days. The median event-free survival (EFS) following CAR T-cell therapy was 7.2 months. Patients aged ≥75 years had significantly shorter EFS compared with patients aged 65 to 69 and 70 to 74 years, with 12-month EFS estimates of 34%, 43%, and 52%, respectively (P = .002). The median overall survival was 17.1 months, and there was no significant difference by age groups. The median total health care cost during the 90-day follow-up was $352 572 and was similar across all age groups. CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was low, especially in patients aged ≥75 years, and this age group had a lower rate of EFS, which illustrates the unmet need for more accessible, effective, and tolerable therapy in older patients, especially those aged ≥75 years.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chihara D, Liao L, Tkacz J, et al. Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma. Blood. 2023. PMID: 37339585. doi:10.1182/blood.2023020197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。